Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia

BACKGROUND: Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remains a critical challenge. Here, we reposition FLT3, one of the most frequently mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Ji Eun, Kim, Soo-Hyun, Kong, Mingyu, Kim, Hwa-Ryeon, Yoon, Sungmin, Kee, Kyung-Mi, Kim, Jung Ah, Kim, Dong Hyeon, Park, So Yeon, Park, Jae Hyung, Kim, Hongtae, No, Kyoung Tai, Lee, Han-Woong, Gee, Heon Yung, Hong, Seunghee, Guan, Kun-Liang, Roe, Jae-Seok, Lee, Hyunbeom, Kim, Dong-Wook, Park, Hyun Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626670/
https://www.ncbi.nlm.nih.gov/pubmed/37932786
http://dx.doi.org/10.1186/s12943-023-01837-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626670/
https://www.ncbi.nlm.nih.gov/pubmed/37932786
http://dx.doi.org/10.1186/s12943-023-01837-4

Ejemplares similares